Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Buy" by Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have earned an average rating of "Buy" from the eight ratings firms that are covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $19.43.

Several analysts have recently issued reports on the company. HC Wainwright increased their price objective on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC increased its stake in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the period. US Bancorp DE increased its stake in shares of Replimune Group by 582.6% during the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after acquiring an additional 3,921 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after acquiring an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd increased its stake in shares of Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after acquiring an additional 8,183 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Replimune Group by 106.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company's stock valued at $111,000 after acquiring an additional 5,876 shares during the period. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Price Performance

NASDAQ:REPL traded down $0.06 during trading hours on Tuesday, hitting $7.71. 1,352,895 shares of the stock were exchanged, compared to its average volume of 899,337. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.00. The firm's fifty day moving average price is $9.36 and its 200 day moving average price is $11.48. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a market cap of $593.79 million, a P/E ratio of -2.51 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities research analysts anticipate that Replimune Group will post -2.97 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.